Decorin Expressed From Herpes Simplex Virus Vector Improves Oncolytic Efficacy in Lung Adenocarcinoma Cells - UTU Research Portal

A1 Refereed original research article in a scientific journal

Decorin Expressed From Herpes Simplex Virus Vector Improves Oncolytic Efficacy in Lung Adenocarcinoma Cells

Authors: Frejborg, Fanny; Palomäki, Jussi; Kalke, Kiira; Orpana, Julius; Koivisto, Oliver; Paavilainen, Henrik; Rosenholm, Jessica M.; Zhang, Hongbo; Hukkanen, Veijo; Järveläinen, Hannu

Publisher: Wiley

Publication year: 2025

Journal: Proteoglycan Research

Journal name in source: Proteoglycan Research

Article number: e70016

Volume: 3

Issue: 1

eISSN: 2832-3556

DOI: https://doi.org/10.1002/pgr2.70016

Web address : https://doi.org/10.1002/pgr2.70016

Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/477870498

Abstract

Decorin (DCN) is a small extracellular proteoglycan with significant oncosuppressive activity. Lung adenocarcinoma is commonly devoid of DCN expression and is a leading cause of cancer mortality globally. As a proof‐of‐concept study for evaluating the oncosuppressive potential of DCN expression in lung adenocarcinoma cells, we constructed an oncolytic herpes simplex virus type 1 (HSV‐1) vector, with a DCN transgene, using a transfection‐infection method. Treatment of the lung adenocarcinoma cell line A549 with this novel DCN‐expressing HSV‐1 vector led to a significantly increased oncolysis of the cells compared to the effect of the parental or control marker virus. These results support the further development of a DCN‐expressing oncolytic HSV‐1 for evaluation in in vivo models for the treatment of lung adenocarcinoma, as well as other types of cancers with underexpressed DCN.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.

Proteoglycan Research - 2025 - Frejborg - Decorin Expressed From Herpes Simplex Virus Vector Improves Oncolytic Efficacy in.pdf

Funding information in the publication:
We thank Soili Jussila at CellCore for the upkeep of the cell stocks. We acknowledge Dr. Wenhui Zhou, Dr. Pekka Kolehmainen, Anja Hjelt, Dr. Roope Huttunen and Salla Alaollitervo (Åbo Akademi University and University of Turku, Turku, Finland) for their supportive aid in this project. The plasmid pRB4794 was a generous gift from Prof. Bernard Roizman, University of Chicago, Chicago, USA. F.F. would like to thank Åbo Akademi University Graduate School for personal funding in the form of PhD salary. The authors would further like to thank the Jane and Aatos Erkko foundation (#170046), Satasairaala Central Hospital, The Wellbeing Services County of Satakunta, Cancer Foundation of Southwestern Finland, State of Finland Research Fund (VTR), Research Council of Finland (project numbers #337531, #347897, #353146), Sigrid Jusélius foundation, The Paulo Foundation and Turku University foundation for funding this project. J.P. would like to thank The Finnish Cultural Foundation, South Ostrobothnia Regional Fund (grant number 10231545), Cancer Association of South-Western Finland (grant date 20211210) and Kauhajoki Cultural Foundation (grant date 20230421) for personal funding. K.K. and V.H. have also been supported by the research project 26004913 from Orion Pharma, Finland. This research is also aligned with the strategic research profiling area “Solutions for Health” at Åbo Akademi University (funded by the Research Council of Finland, #336355).